Abstract CT109: A phase I/Ib study evaluating GDC-0077 plus fulvestrant in patients withPIK3CA-mutant, hormone receptor-positive/HER2-negative breast cancer

待确认 20 由 yv 发布于 2026/1/14 10:11:25

DOI:10.1158/1538-7445.am2020-ct109
作者：K. Kalinsky,?D. Juric,?Philippe Bédard,?Mafalda Oliveira,?A. Cervantes,?E. Hamilton,?I. Krop,?N. Turner,?P. Schmid,?A. Varga,?A. Italiano,?Zachary W. Veitch,?C. Saura,?V. Gambardella,?S. Cheeti,?N. K
文献类型：期刊论文
补充材料：只需要正文

American Association for Cancer Research (AACR)

Abstract：Background:PIK3CA encodes the PI3K p110α subunit, and dysregulating mutations are widely seen in breast cancer (BC) and other solid tumors. GDC-0077 (G) is a potent p110α-selective inhibitor

应助信息

等待求助人确认

求助人未确认前，本求助不能再次应助。36小时后系统将自动确认应助成功。本求助将自动关闭。

9小时前

扭扭车

202601141356096099847.pdf

13小时前

Book学术机器人

2026/1/14 10:11:25 未找到该文献，机器人已退出，请等待人工下载

2026/1/14 10:11:25 Book学术AI机器人收到请求，开始寻找文献

2026/1/14 10:11:25 已向机器人发送请求

13小时前

yv 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierIntegrating lipidomics and metabolomics to reveal biomarkers of fat deposition in chicken meat